Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 to $17 per share. The California biotech announced its IPO intentions ...
Checking in on our late-stage bull market scorecard… new IPO madness… margin debt hits record highs… the single-stock ETF explosion… why we’re still dancing (but closer to the exit) Last fall, we ...